Skip to search formSkip to main contentSkip to account menu

IMC-11F8

Known as: Anti-Epidermal Growth Factor Receptor Monoclonal Antibody IMC-11F8, IMC-11F8 monoclonal antibody 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

necitumumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer
Over the past two decades, progress in the treatment of patients with metastatic squamous non-small-cell lung cancer has been… 
2015
2015
Necitumumab May Improve Overall Survival in Patients with Squamous NSCLC
Adding necitumumab (IMC-11F8) to gemcitabine (Gemzar) and cisplatin chemotherapy may improve overall survival (OS) in patients… 
2011
2011
Abstract 5030: Necitumumab (IMC-11F8), a recombinant human anti EGFR antibody, increases the antitumor effects of cisplatin/paclitaxel in human NSCLC xenograft models
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Epidermal growth factor receptor (EGFR) targeted… 
2010
2010
85 Mechanisms underlying the therapeutic benefit of necitumumab (IMC-11F8) in combination with cisplatin/gemcitabine in NSCLC xenograft models
2009
2009
Abstract #2774: The fully human EGFR antibody IMC-11F8 significantly increases the antitumor effects of cisplatin+gemcitabine in human non-small cell lung cancer models
Platinum based chemotherapy regimens have demonstrated superior or equivalent efficacy to that of alternative combination… 
2008
2008
A phase II multicenter study evaluating the efficacy and safety of IMC-11F8, a recombinant human IgG1 anti- epidermal growth factor receptor (EGFR) monoclonal antibody (Mab), combined with 5-FU/FA…
2008
2008
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2007
2007
A phase I study of IMC-11F8, a recombinant human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors
B52 Background: This phase I study was conducted to determine the safety profile and recommended dose of IMC-11F8, a recombinant… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)